Skip to content
Screener

Nuvation Bio NUVB Short-Term Borrowings

Short-Term Borrowings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.03B-78.2%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ShortTermBorrowings.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646

FAQ

What is Nuvation Bio's short-term borrowings?
Nuvation Bio (NUVB) reported short-term borrowings of $5.89M in Q2 2026.
How has Nuvation Bio's short-term borrowings changed year-over-year?
Nuvation Bio's short-term borrowings increased by 5.6% year-over-year, from $5.58M to $5.89M.
What does short-term borrowings mean?
Bank lines of credit, revolving credit facilities, and other short-term debt instruments with maturities under one year.

Ask your AI about Nuvation Bio's short-term borrowings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude